Exploration of Medicine (Aug 2020)

Non-alcoholic fatty liver disease and transient elastography

  • Ivana Mikolasevic,
  • Andela Lukic,
  • Toni Juric,
  • Mia Klapan,
  • Petra Madzar,
  • Nikola Krolo,
  • Doris Kolovrat,
  • Ivanka Jurica,
  • Iva Kedmenec,
  • Domagoj Kihas,
  • Doris Ilovaca,
  • Ivan Erstic,
  • Vanda Haralovic,
  • Danijel Cavlina,
  • Ema Dejhalla,
  • Danijela Erdeljac,
  • Benjamin Vukalovic,
  • Nadija Skenderevic,
  • Sandra Milic

DOI
https://doi.org/10.37349/emed.2020.00014
Journal volume & issue
Vol. 1, no. 4
pp. 205 – 217

Abstract

Read online

Nonalcoholic fatty liver disease (NAFLD) is a serious condition that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. NAFLD is associated with metabolic syndrome (MetS) and all of its components. According to data, around 25–30% of population has NAFLD. Giving the growing incidence of MetS, obesity and diabetes mellitus type 2, NAFLD related terminal-stage liver disease is becoming prevailing indication for liver transplantation. In order to prevent terminal stage of this disease, it is crucial to determine those that are in risk group, to modify their risk factors and monitor their potential progression. In the absence of other causes of chronic liver disease, the prime diagnosis of NAFLD in daily clinical practice includes anamnesis, laboratory results (increased levels of aminotransferases and gammaglutamil transferases) and imaging methods. The biggest challenge with NAFLD patients is to differentiate simple steatosis from nonalcoholic steatohepatitis, and detection of fibrosis, that is the main driver in NAFLD progression. The gold standard for NAFLD diagnosis still remains the liver biopsy (LB). However, in recent years many noninvasive methods were invented, such as transient elastography (TE). TE (FibroScan®, Echosens, Paris, France) is used for diagnosis of pathological differences of liver stiffness measurement (LSM) and controlled attenuation parameter (CAP). Investigations in the last years have confirmed that elastographic parameters of steatsis (CAP) and fibrosis (LSM) are reliable biomarkers to non-invasively assess liver steatosis and fibrosis respectively in NAFLD patients. A quick, straightforward and non-invasive method for NAFLD screening in patients with MetS components is TE-CAP. Once diagnosed, the next step is to determine the presence of fibrosis by LSM which should point out high risk patients. Those patients should be referred to hepatologists. LB may be avoided in a substantial number of patients if TE with CAP is used for screening.

Keywords